S J H Vijverberg1,2, E S Koster1, R Tavendale3, M Leusink1, L Koenderman2, J A M Raaijmakers1, D S Postma4, G H Koppelman5, S W Turner6, S Mukhopadhyay3,7, S M Tse8,9, K G Tantisira8, D B Hawcutt10, B Francis11, M Pirmohamed12, M Pino-Yanes13,14, C Eng13, E G Burchard13,15, C N A Palmer3, A H Maitland-van der Zee1. 1. Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht, The Netherlands. 2. Department of Respiratory Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands. 3. Population Pharmacogenetics Group, Biomedical Research Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK. 4. Department of Pulmonology, Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 5. Department of Paediatric Pulmonology and Paediatric Allergology, Beatrix Children's Hospital, Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 6. Department of Child Health, University of Aberdeen, Aberdeen, UK. 7. Academic Department of Paediatrics, Royal Alexandra Children's Hospital, Brighton and Sussex Medical School, Brighton, UK. 8. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 9. Sainte- Justine University Health Center, Montreal, Quebec, Canada. 10. Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK. 11. Department of Biostatistics, University of Liverpool, Liverpool, UK. 12. Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK. 13. Department of Medicine, University of California, San Francisco, CA, USA. 14. CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain. 15. Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
Abstract
BACKGROUND: The clinical response to inhaled corticosteroids (ICS) is associated with single nucleotide polymorphisms (SNPs) in various genes. This study aimed to relate variations in genes in the steroid pathway and asthma susceptibility genes to exacerbations in children and young adults treated with ICS. METHODS: We performed a meta-analysis of three cohort studies: Pharmacogenetics of Asthma Medication in Children: Medication with Anti-Inflammatory effects (n = 357, age: 4-12 years, the Netherlands), BREATHE (n = 820, age: 3-22 years, UK) and Paediatric Asthma Gene Environment Study (n = 391, age: 2-16 years, UK). Seventeen genes were selected based on a role in the glucocorticoid signalling pathway or a reported association with asthma. Two outcome parameters were used to reflect exacerbations: hospital visits and oral corticosteroid (OCS) use in the previous year. The most significant associations were tested in three independent validation cohorts; the Childhood Asthma Management Programme (clinical trial, n = 172, age: 5-12 years, USA), the Genes- environment and Mixture in Latino Americans II- study (n = 745, age: 8-21, USA) and the Pharmacogenetics of adrenal suppression cohort (n = 391, age: 5-18, UK) to test the robustness of the findings. Finally, all results were meta-analysed. RESULTS: Two SNPs in ST13 (rs138335 and rs138337), but not in the other genes, were associated at a nominal level with an increased risk of exacerbations in asthmatics using ICS in the three cohorts studied. In a meta-analysis of all six studies, ST13 rs138335 remained associated with an increased risk of asthma-related hospital visits and OCS use in the previous year; OR = 1.22 (P = 0.013) and OR = 1.22 (P = 0.0017), respectively. CONCLUSION AND CLINICAL RELEVANCE: A novel susceptibility gene, ST13, coding for a cochaperone of the glucocorticoid receptor, is associated with exacerbations in asthmatic children and young adults despite their ICS use. Genetic variation in the glucocorticoid signalling pathway may contribute to the interindividual variability in clinical response to ICS treatment in children and young adults.
BACKGROUND: The clinical response to inhaled corticosteroids (ICS) is associated with single nucleotide polymorphisms (SNPs) in various genes. This study aimed to relate variations in genes in the steroid pathway and asthma susceptibility genes to exacerbations in children and young adults treated with ICS. METHODS: We performed a meta-analysis of three cohort studies: Pharmacogenetics of Asthma Medication in Children: Medication with Anti-Inflammatory effects (n = 357, age: 4-12 years, the Netherlands), BREATHE (n = 820, age: 3-22 years, UK) and Paediatric Asthma Gene Environment Study (n = 391, age: 2-16 years, UK). Seventeen genes were selected based on a role in the glucocorticoid signalling pathway or a reported association with asthma. Two outcome parameters were used to reflect exacerbations: hospital visits and oral corticosteroid (OCS) use in the previous year. The most significant associations were tested in three independent validation cohorts; the Childhood Asthma Management Programme (clinical trial, n = 172, age: 5-12 years, USA), the Genes- environment and Mixture in Latino Americans II- study (n = 745, age: 8-21, USA) and the Pharmacogenetics of adrenal suppression cohort (n = 391, age: 5-18, UK) to test the robustness of the findings. Finally, all results were meta-analysed. RESULTS: Two SNPs in ST13 (rs138335 and rs138337), but not in the other genes, were associated at a nominal level with an increased risk of exacerbations in asthmatics using ICS in the three cohorts studied. In a meta-analysis of all six studies, ST13 rs138335 remained associated with an increased risk of asthma-related hospital visits and OCS use in the previous year; OR = 1.22 (P = 0.013) and OR = 1.22 (P = 0.0017), respectively. CONCLUSION AND CLINICAL RELEVANCE: A novel susceptibility gene, ST13, coding for a cochaperone of the glucocorticoid receptor, is associated with exacerbations in asthmatic children and young adults despite their ICS use. Genetic variation in the glucocorticoid signalling pathway may contribute to the interindividual variability in clinical response to ICS treatment in children and young adults.
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: Ellen S Koster; Jan Am Raaijmakers; Gerard H Koppelman; Dirkje S Postma; Cornelis K van der Ent; Leo Koenderman; Madelon Bracke; Anke Hilse Maitland-van der Zee Journal: Pharmacogenomics Date: 2009-08 Impact factor: 2.533
Authors: Gonçalo R Abecasis; David Altshuler; Adam Auton; Lisa D Brooks; Richard M Durbin; Richard A Gibbs; Matt E Hurles; Gil A McVean Journal: Nature Date: 2010-10-28 Impact factor: 49.962
Authors: Kelan G Tantisira; Eric S Silverman; Thomas J Mariani; Jingsong Xu; Brent G Richter; Barbara J Klanderman; Augusto A Litonjua; Ross Lazarus; Lanny J Rosenwasser; Anne L Fuhlbrigge; Scott T Weiss Journal: J Allergy Clin Immunol Date: 2007-11-05 Impact factor: 10.793
Authors: Blanca E Himes; Gary M Hunninghake; James W Baurley; Nicholas M Rafaels; Patrick Sleiman; David P Strachan; Jemma B Wilk; Saffron A G Willis-Owen; Barbara Klanderman; Jessica Lasky-Su; Ross Lazarus; Amy J Murphy; Manuel E Soto-Quiros; Lydiana Avila; Terri Beaty; Rasika A Mathias; Ingo Ruczinski; Kathleen C Barnes; Juan C Celedón; William O C Cookson; W James Gauderman; Frank D Gilliland; Hakon Hakonarson; Christoph Lange; Miriam F Moffatt; George T O'Connor; Benjamin A Raby; Edwin K Silverman; Scott T Weiss Journal: Am J Hum Genet Date: 2009-05-07 Impact factor: 11.025
Authors: Augusto A Litonjua; Jessica Lasky-Su; Kady Schneiter; Kelan G Tantisira; Ross Lazarus; Barbara Klanderman; John J Lima; Charles G Irvin; Stephen P Peters; John P Hanrahan; Stephen B Liggett; Gregory A Hawkins; Deborah A Meyers; Eugene R Bleecker; Christoph Lange; Scott T Weiss Journal: Am J Respir Crit Care Med Date: 2008-07-10 Impact factor: 21.405
Authors: Gregory A Hawkins; Ross Lazarus; Richard S Smith; Kelan G Tantisira; Deborah A Meyers; Stephen P Peters; Scott T Weiss; Eugene R Bleecker Journal: J Allergy Clin Immunol Date: 2009-02-28 Impact factor: 10.793
Authors: Albert M Levin; Hongsheng Gui; Natalia Hernandez-Pacheco; Mao Yang; Shujie Xiao; James J Yang; Samantha Hochstadt; Andrea J Barczak; Walter L Eckalbar; Dean Rynkowski; Lesly-Anne Samedy; Pui-Yan Kwok; Maria Pino-Yanes; David J Erle; David E Lanfear; Esteban G Burchard; L Keoki Williams Journal: J Allergy Clin Immunol Date: 2018-10-24 Impact factor: 10.793
Authors: Steve Turner; Ben Francis; Nuha Wani; Susanne Vijverberg; Maria Pino-Yanes; Somnath Mukhopadhyay; Roger Tavendale; Colin Palmer; Esteban G Burchard; Simon Kebede Merid; Erik Melén; Anke H Maitland-van der Zee; On Behalf Of The Pharmacogenomics In Childhood Asthma Consortium Journal: Pharmacogenomics Date: 2018-05-22 Impact factor: 2.533
Authors: Steve Turner; Ben Francis; Susanne Vijverberg; Maria Pino-Yanes; Anke H Maitland-van der Zee; Kaninika Basu; Lauren Bignell; Somnath Mukhopadhyay; Roger Tavendale; Colin Palmer; Daniel Hawcutt; Munir Pirmohamed; Esteban G Burchard; Brian Lipworth Journal: J Allergy Clin Immunol Date: 2016-01-07 Impact factor: 10.793
Authors: Amber Dahlin; Joshua Denny; Dan M Roden; Murray H Brilliant; Christie Ingram; Terrie E Kitchner; James G Linneman; Christian M Shaffer; Peter Weeke; Hua Xu; Michiaki Kubo; Mayumi Tamari; George L Clemmer; John Ziniti; Michael J McGeachie; Kelan G Tantisira; Scott T Weiss; Ann Chen Wu Journal: Immun Inflamm Dis Date: 2015-07-14